All In Biotech

Drug Trial Radar · NCT07118878

A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants

A Phase 1, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of AGMB-129 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Aug 6, 2025

Primary completion

Sep 15, 2025

Study completion Sep 15, 2025

Sponsor

Lead sponsor
Agomab Spain S.L.U.Industry
Sponsor type
Industry
First posted
Aug 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In patients with Crohn's disease (CD), fibrosis of the gastrointestinal (GI) tract can result in stricture (stenosis) formation and obstruction of the GI tract, causing obstructive symptoms and often requiring surgical intervention. There are currently no approved therapies for treating fibrostenotic Crohn's disease (FSCD) and therefore, there is an urgent need for safe and effective antifibrotic therapies. AGMB-129 has shown to be safe in healthy participants with single doses up to 1200 mg and multiple doses up to 200 mg twice daily (BID) for 10 days, and in FSCD patients with multiple doses up to 200 mg BID for 12 weeks. This Phase 1 study will explore the safety, tolerability, and pharmacokinetics (PK) of other daily doses of AGMB-129 in healthy participants to inform on dose selection (nominal dose and dosing frequency) for subsequent clinical trials.

Conditions

  • Fibrostenotic Crohn's Disease

Interventions

  • AGMB-129Drug

    AGMB-129

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participant with Adverse EventsTime frame: From enrollment to the end of treatment at 42 days
  2. Number of participant with abnormal Physical examinationTime frame: From enrollment to the end of treatment at 42 days
  3. Number of participant with abnormal Vital signsTime frame: From enrollment to the end of treatment at 42 days
  4. Number of participant with abnormal electrocardiograms (ECGs) parametersTime frame: From enrollment to the end of treatment at 42 days
  5. Number of participant with abnormal 2-dimensional (2-D) echocardiographyTime frame: From enrollment to the end of treatment at 42 days
  6. Number of participant with abnormal clinical laboratory testsTime frame: From enrollment to the end of treatment at 42 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SGS Belgium

    Edegem, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.